KEYNOTE-905: Perioperative Immunotherapy Regimen Active in Cisplatin-Ineligible MIBC - Takeaways - MDSpire
Clinical Guidelines
Feature

KEYNOTE-905: Perioperative Immunotherapy Regimen Active in Cisplatin-Ineligible MIBC

A perioperative regimen of enfortumab vedotin-ejfv plus pembrolizumab significantly improved survival and pathologic complete response rates compared to radical cystectomy alone in patients with muscl...

  • By

  • Chase Doyle

  • May 8, 2026

  • 6 min

Share

  • 1

    The KEYNOTE-905 trial examined enfortumab vedotin and pembrolizumab for MIBC.

  • 2

    Significant improvements in event-free and overall survival were reported.

  • 3

    Pathologic complete response rate with the combination was 57.1%.

  • 4

    FDA approved the regimen due to its efficacy.

  • 5

    Nearly 80% of participants were cisplatin-ineligible with higher age/complexities.

  • 6

    Safety profile was manageable, consistent with previous results.

  • 7

    344 patients were randomized in the study.

  • 8

    The treatment impacts surgical outcomes minimally.

Original Source(s)

KEYNOTE-905: Perioperative Immunotherapy Regimen Active in Cisplatin-Ineligible MIBC

  • by Chase Doyle

  • May 8, 2026

Related Content

Acupuncture for Nocturia in Survivors of Prostate Cancer

Guest Editor’s Note: Nocturia, waking up from sleep more than once to urinate, is prevalent in survivors of prostate cancer and is associated with a diminished quality of life and a higher mortality t...

Gerald Hsu, MD, PhD, Named Editor-in-Chief of the ASCO Educational Book

ASCO is pleased to announce the appointment of Gerald Hsu, MD, PhD, as the new Editor-in-Chief of the ASCO Educational Book.    

  • by ASCO

  • May 8, 2026

  • 2 min
National Academy of Medicine Recognizes 100 Newly Elected Members

Election to the National Academy of Medicine recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.